Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi winthrop industrie - liksisenatid - diabetes mellitus, tip 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astra zeneca ab - saxagliptin, dapagliflozin propanediol monohidrat - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - zdravila, ki se uporabljajo pri diabetesu - qtern, fiksni odmerek kombinacija saxagliptin in dapagliflozin, je navedeno pri odraslih, starih 18 let in več, z vrsto 2 sladkorna bolezen:za izboljšanje glycaemic nadzor, ko metforminom in/ali sulfonil sečnine (su) in eden od monocomponents od qtern ne zagotavljajo ustrezne glycaemic nadzor,ko se že zdravijo z brezplačno kombinacija dapagliflozin in saxagliptin. (glej točki 4. 2, 4. 4, 4. 5 in 5. 1, če so na voljo podatki o kombinacije študiral.

Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin, metformin hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - vokanamet je navedeno pri odraslih, starih 18 let in več, z vrsto 2 sladkorna bolezen kot dodatek k prehrani in vadbi za izboljšanje glycaemic nadzor:pri bolnikih, ki ni ustrezno nadzorovana na njihovo maksimalno dopustne koncentracije metforminom alonein bolnikov na njihovo maksimalno dopustne koncentracije metforminom skupaj z drugimi glukoze znižanje medicini, vključno z insulina, ko te ne zagotavljajo ustrezne glycaemic nadzor. pri bolnikih, ki se že zdravijo z kombinacijo canagliflozin in metforminom kot ločene tabletsfor študijski rezultati glede kombinacija terapij, vplivi na glycaemic nadzor in srčno-žilne dogodke, in populacije, ki je študiral glej poglavji 4. 4, 4. 5 in 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - pioglitazone, glimepiride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - tandemact je indicirano za zdravljenje bolnikov s sladkorno boleznijo tipa 2, ki kažejo nestrpnosti v metforminom ali za katere je kontraindiciran metformin in ki se že zdravijo s kombinacijo pioglitazone in glimepiride.

Evropska unija - slovenščina - EMA (European Medicines Agency)

actavis group ptc ehf   - pioglitazon hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. po začetku terapije z pioglitazone, bolnike je treba pregledati in po 3 do 6 mesecev, da oceni ustreznost odziva na zdravljenje (e. zmanjšanje hba1c). pri bolnikih, ki ne kažejo ustrezen odgovor, pioglitazone, je treba prekiniti,. v luči možnih tveganj z dolgotrajna terapija, predpisovalce morajo potrditi na kasnejše redne preglede, da je korist pioglitazone je ohranjena (glej poglavje 4.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim - empagliflozin, metformin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - synjardy je navedeno pri odraslih, starih 18 let in več, z vrsto 2 sladkorna bolezen kot dodatek k prehrani in vadbi za izboljšanje glycaemic nadzor:pri bolnikih, neustrezno nadzorovano na njihovo maksimalno dopustne odmerek metforminom sam;pri bolnikih, neustrezno nadzorovana z metforminom v kombinaciji z drugimi glukoze-znižanje zdravil, vključno z insulina;pri bolnikih, ki se že zdravijo z kombinacijo empagliflozin in metforminom kot ločene tablete.

Evropska unija - slovenščina - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin - diabetes mellitus, tip 2 - drugs used in diabetes, dipeptidyl peptidase 4 (dpp-4) inhibitors - vipidia je navedeno pri odraslih, starih 18 let in starejši s sladkorno boleznijo tipa 2 za izboljšanje nadzora glycaemic v kombinaciji z drugimi glukoze, zniževanje zdravila, vključno z insulinom, ko ti, skupaj z dieto in telesno vadbo, ne zagotavljajo ustrezne glycaemic nadzor (glej točki 4. 4, 4. 5 in 5. 1 za razpoložljive podatke o različnih kombinacijah).

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 in 5. 1 za razpoložljive podatke o različnih kombinacijah).

Evropska unija - slovenščina - EMA (European Medicines Agency)

amryt pharmaceuticals dac - metreleptin - lipodystrophy, družinsko delno - drugi zdravljene bolezni prebavil in presnove izdelki, - myalepta je indicirano kot dodatek k dieti kot nadomestno zdravljenje za zdravljenje zapletov leptin pomanjkljivost v lipodystrophy (ld) bolnikov:s potrjeno prirojene splošnih ld (berardinelli-seip sindrom) ali pridobljenih splošnih ld (lawrence sindrom) pri odraslih in otrok do 2 let starosti in abovewith potrdili družinsko delno ld ali pridobljeno delno ld (barraquer-simons sindrom), pri odraslih in otrok 12 let in zgoraj za katere standardno zdravljenje ni uspelo doseči ustrezno presnovno nadzor.